Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine

Shares of Moderna, Inc. (MRNA) were down 4.4% on May 10 after the company announced that the FDA has delayed the review timeline for its mRNA-based, respiratory syncytial virus (RSV) vaccine, mRNA-1345. Moderna has developed mRNA-1345 for use in older adults (aged 60 years and above). The regulatory body notified the company that due to administrative constraints, it would not be able to complete the review of the biologics license application (BLA) for mRNA-1345 by the Prescription Drug User Fee Act date o ...